Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth, and may stimulate the immune system to stop cancer cells from
growing.
PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat after
stem cell transplant in treating patients with high-risk lymphoma.